provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. ICAD stock was trading flat after Thursday’s market close.Īs of this writing, Karl Utermohlen did not hold a position in any of the aforementioned securities.ICAD, Inc. The company’s adjusted EBITDA was a loss of $4.8 million. ICAD had a net loss of $14.3 million for the year, or 87 cents per share.
#Icad inc stock full#
Its gross profit amounted to $19.2 million for the full year, or 68%, excluding a $1 million inventory reserve. Revenue for the company’s full year was $28.1 million, increasing 7% year-over-year. Its adjusted EBITDA came in at a loss of $1.3 million. ICAD also unveiled a GAAP net loss of $4.2 million, or 26 cents per share, including a non-cash goodwill and long-lived asset impairment charge of roughly $2 million. Its gross profit was $5.3 million, or 68%, for the quarter that ended the fiscal year 2017.
The company’s fourth quarter brought in revenue of $7.9 million, a 14% increase compared to the year-ago quarter. iCAD Inc (ICAD)Īnd iCAD also reported for its latest quarter yesterday.
HTGM shares slipped 1.1% after hours yesterday. Net loss for the year was $1.79 per share, compared to $3.66 per share in the year-ago period. HTG Molecular Diagnostics posted a net loss of $19 million for the fiscal year, below its year-ago loss of $26 million. Net loss from operations for the year was $17.7 million, compared to $24.3 million in the year-ago quarter. This amounted to a net loss of 15 cents per share, compared to a loss of 76 cents per share in the year-ago quarter.įor the fiscal year, the company posted revenue of $14.8 million, topping the year-ago revenue of $5.1 million. HTG Molecular Diagnostics posted a net loss of $1.9 million during its fourth quarter, compared to a loss of $5.7 million in the year-ago quarter. Fourth-quarter net loss from operations was $1.7 million, compared to a $5.2 million loss in the year-ago quarter. The company unveiled fourth-quarter revenue of $7.9 million, more than quadruple the year-ago net revenue of $1.5 million. HTG Molecular Diagnostics released its latest quarterly results, posting a loss. HOME stock gained more than 6% after the bell Thursday.
#Icad inc stock pro#
Earnings were 15 cents per share, 10 cents below the year-ago quarter, while pro forma adjusted earnings surged 78.6% to 50 cents per share. Net income was $15.3 million in the year-ago period.Īt Home Group’s pro forma adjusted net income surged 85.6% to $32.3 million from $17.4 million in the fourth quarter of fiscal 2017. Net income came in at $9.9 million during the period, including non-cash charges of $16.7 million in tax expense due to changes in the U.S. This marks a 21.1% surge in store count year-over-year. Its fourth quarter included the net addition of 26 stores year-over-year, as well as a comparable store sales boost of 5.7%.Īt Home Group opened five new stores in the fourth quarter of fiscal 2018, pushing their total to 149 stores in 34 states. The company’s net sales surged 25.2% year-over-year to $293.7 million from the year-ago total of $234.5 million. Several companies reported on their latest quarters late Thursday, including At Home Group Inc (NYSE: HOME), HTG Molecular Diagnostics Inc (NASDAQ: HTGM) and iCAD Inc (NASDAQ: ICAD).Īt Home Group’s earnings increased year-over-year, sending shares higher late in the day. The index fell 2.9% Thursday, while the S&P 500 Index fell 2.5% and the Nasdaq Composite fell 2.4%. equities in which President Donald Trump announced tariffs on international imports from China. The Dow Jones Industrial Average dropped more than 700 points on a down day for U.S.